News

BMS enters deal with Santharis
Enlarge image

BusinessDenmark

BMS enters deal with Santharis

17.04.2013 - Danish Santaris Pharma A/S has entered a global strategic R&D collaboration with BristolMyers Squibb in the field of RNA drugs.

Santaris said it will use its Locked Nucleic Acid (LNA) platform to discover and develop new mRNA or microRNA drug candidates. Under the terms of the agreement, the Horsholm-based company will get US$10 upfront and up to US$90m of milestone payments. Furthermore, the drug developer will be eliglible to receive royalties on worldwide sales araising from the alliance.  

In successful cases, BMS will gain the exclusive global marketing rights. Further financial details were not disclosed by the companies. Santaris Pharma's LNA platform A/S combines the company's proprietary LNA chemistry with its highly specialised and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including infectious and inflammatory diseases, cardiometabolic disorders, cancer and rare genetic disorders.  

RNA-based drugs are a promising new class of therapeutics that are enabling scientists to develop drug candidates that target previously inaccessible clinical pathways. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states

The network will advise SMEs on how to get financial support for projects at a pilot plant in Ghent. This flexible pilot plant will selectively invest in equipment for promising technologies to promote further growth. The partnership will also develop and deliver programmes and tools for training skilled professionals for bio-based industries.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/bms-enters-discovery-deal-with-santharis.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR33.6%
  • CO.DON3.14 EUR27.6%
  • FORMYCON8.20 EUR16.3%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.10 EUR-16.7%
  • MOLOGEN6.60 EUR-12.8%

TOP

  • SANTHERA86.95 CHF2146.8%
  • PAION3.22 EUR238.9%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.3%
  • MOLOGEN6.60 EUR-44.5%
  • 4SC1.04 EUR-44.4%

No liability assumed, Date: 01.10.2014